Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sciclone pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Captain Jack who wrote (884)	8/20/2001 9:16:03 PM
From: Oak Tree	Read Replies (1) \| Respond to of 1137

Gosh we have some real believers in biotech. Hate to say it, but Sciclone isn't even on the radar screen for most doctors. C225 on the other hand has lots of interst and hype, so even if it barely works lots of patients and doctors will use it for a few years. Both drug Co's have a huge number of competitors, other competitors are already dead (or are simply refusing to die but should be gone). Sciclone is a penny in a few months, Imclone in a few years. Sorry but I don't buy Jeb's scientific review of cancer therapy.